Escient’s pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), and EP547, a first-in-class oral MRGPRX4 antagonist.
“EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases, and additional potential launch opportunities starting in 2029,” said Hervé Hoppenot, Incyte’s CEO.
With this update, Cantor Fitzgerald has initiated coverage on Incyte with a Neutral rating.
The Cantor analyst suggests that Incyte’s shares are undervalued primarily due to the cash and expected cash flow from Jakafi and Opzelura but expresses reservations about the company’s pipeline prospects.
However, Incyte’s stock has declined by 31% in the past year due to concerns about the 2029 patent expiration for Jakafi, its high-margin drug.
Both growth and value investors are hesitant to support the company’s current strategy. Value investors particularly note Incyte’s reluctance to return cash to shareholders. A major stock buyback before pivotal pipeline updates could alleviate concerns and bolster valuation.
The analyst questions Incyte’s ability to allocate over 40% of its revenue to R&D efficiently and suggests prioritizing high-return pipeline candidates.
Cantor highlights the potential value of acquiring U.S. rights to MorphoSys AG’s
Despite optimism for certain pipeline assets like povorcitinib, the analyst remains cautious about others lacking differentiation or strong scientific rationale.
William Blair suggests that although the approval of another significant asset by the end of the decade will benefit Incyte in the long term, investors are seeking assets that can generate revenue before the patent exclusivity of Jakafi expires in 2028.
They maintain their positive outlook on Incyte, emphasizing that favorable Phase 3 results with povorcitinib in hidradenitis suppurativa in 2025 could alter perceptions and reaffirm their recommendation to Outperform.
Regarding the Escient deal, William Blair highlights the intriguing potential of the MRGPRX2 target. Initial data in chronic inducible urticaria suggests that EP262 complements the company’s existing inflammation and immunology franchises, tapping into significant market opportunities.
The assist to so-called “mixed-status couples” is seen as another concession to would-be Democratic voters ahead of the Nov. 5 election — and would follow potential executive action by Biden to tighten border security, the Wall Street Journal reports.
The outlet added that administration officials believe any backlash over an amnesty order would be tempered by voter sympathy for the couples.
President Biden’s administration is considering granting deportation relief to more than one million people who entered the US illegally before marrying American citizens, according to a report.REUTERS
A final decision is not imminent, but the Journal reported the idea has been gaining traction since the summer of 2023.
According to the immigration advocacy group Fwd.us, around 1.1 million illegal immigrants are married to American citizens.
While immigrants who marry Americans typically qualify for green cards, many “mixed-status” couples have one partner who is ineligible for legal permanent residency for various reasons — including entering the US illegally more than once or using forged legal papers.
Should the White House go forward with its plan, it is likely to implement a “parole in place” program, a version of which already allows spouses, parents or children of active-duty military and veterans toremain in the US in one-year increments, per the WSJ.
Any program would also only apply to those who entered the country unlawfully, as opposed to someone who immigrated legally and overstayed their visa, according to the report.
In addition, the potential order is expected to only apply to couples who have been married a set amount of time, such as five or 10 years.
Around 1.1 million illegal immigrants are married to American citizens, according to the immigration advocacy group Fwd.us.James Breeden for New York Post
The president has not committed to pushing out an executive action to crack down on border crossings — and has noted he’s not sure he has the ability to do so.
The White House has been calling on Congress to pass a bipartisan bill that would include border security funding — blaming the Republican majority in the House for blocking the bill from going forward — while White House press secretary Karine Jean-Pierre has said an executive action would pale in comparison to Congressional funding.
“There is no executive action — no executive action that the President can take — no matter how aggressive it could be, can deliver the significant policy reforms and additional — additional resources that Congress could have provided that Republicans rejected,” she said at a press briefing in February.
Republicans have insisted that Biden has all of the powers he needs to secure the border, but refuses to use them.
Texas National Guard pushed back a large group of almost 60 migrants who crossed the border illegally and breached the concertina wire barriers set up along the US side of the Rio Grande river.James Breeden for NY Post
“The current administration has continually ignored any provisions of the Immigration and Nationality Act (INA) that it dislikes on ideological grounds — and has attempted to unilaterally rewrite immigration law without the participation of Congress,” Matt O’Brien, the director of the conservative Immigration Reform Law Institute and a former immigration judge, told The Post.
“This is a continuation of an abusive trend, which began with DACA, and has now progressed to deliberate misuse of the parole authority and deferred enforced departure,” O’Brien added. “I shudder to think what comes next.”
“The INA is very clear, people who broke our immigration laws don’t get a free pass simply because they marry a US citizen or have a child on US soil. And the White House has no authority to unilaterally give them one,” O’Brien argued.
“There are already processes in place for the immigrant spouses of American citizens to obtain legal status,” agreed Ken Cuccinelli, a former top DHS official in the Trump administration and senior fellow at the Center for Renewing America. “They are rife with fraud that needs to be fixed, which I doubt this administration is interested in, so I suspect this is just another aspect of our immigration system that Joe Biden seems intent on making worse instead of fixing.”
The White House did not immediately respond to an inquiry from The Post.
Polls have consistently shown immigration to be a top issue for voters this election cycle, with a Gallup survey showing that it was the most important question for 28% of voters in March, behind only the economy (30%).
Incyteannounced Tuesday that it isbuyingEscient Pharmaceuticalsfor $750 million to gain control of a pipeline led by clinical-phase treatments of atopic dermatitis and other skin conditions.
Escient’s lead asset is an antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor that is expressed on mast cells. Because the receptor mediates the activation of mast cells and their response to wounding, Escient identified the target as the method for improving outcomes in the skin conditions atopic dermatitis, chronic inducible urticaria and chronic spontaneous urticaria. The small molecule, EP262, is in Phase Ib/II trials in those three conditions and clinical proof-of-concept data are due early in 2025.
Incyte is buying Escient after seeing the results of preclinical studies that showed EP262 improves atopic dermatitis-like skin lesions and markers of Type II inflammation, plus data from a Phase I clinical trial in healthy volunteers. No subjects had serious or severe adverse events, side effects that forced them to stop taking the molecule or clinically meaningful adverse changes in various parameters.
Escient is also developing a MRGPRX4 antagonist in cholestatic pruritus and uremic pruritus, the medical names for itching caused by liver and kidney disease. MRGPRX4 is found on neurons that are implicated in itch and are activated by molecules that accumulate in patients with liver and kidney disease. Escient identified the receptor as the way to treat forms of itching in which antihistamines and other drugs are ineffective. Clinical proof-of-concept data on EP547 in cholestatic pruritus are due early in 2025.
If the Phase II trials of EP262 and EP547 are successful, Incyte plans to start pivotal trials of the assets in a range of indications between 2025 and 2027. The studies could lead to a series of approvals around the end of the decade.
“With this acquisition, we will be able to leverage our existing development and commercial capabilities. In addition, these programs offer a large potential commercial opportunity across multiple indications,” Incyte CEO Hervé Hoppenot said on a Tuesday call with investors to discuss the deal. “The two lead assets ... address large populations with a clear medical need and a multibillion-dollar total market opportunity.”
The buyout is expected to close by the third quarter of 2024.
The timing of the anticipated potential approvals means EP262 and EP547 are scheduled to start adding to sales at Incyte after patents on its key drug Jakafi (ruxolitinib) expire in 2028. Hoppenot said the company is still looking to bring in other assets and the Escient buyout will not prevent Incyte from “doing additional and larger acquisitions in the future.”
Despite being slapped down by the U.S. Court of Appeals for ordering a Jan. 6 probationer’s computer use be monitored for so-called “disinformation,” a senior federal judge in Washington D.C. appears ready to reimpose the restriction on Daniel Goodwyn of Corinth, Texas.
Senior U.S. District Judge Reggie Walton ordered Mr. Goodwyn to “show cause” for why the computer monitoring provision should not be reimposed. Judge Walton set a June 4 hearing date on the issue in Washington.
Defense attorney Carol Stewart said Mr. Goodwyn’s appeal and the Court of Appeals ruling include the statute and relevant case law that explain why computer monitoring in this case is unconstitutional.
“The matter should be closed in my view,” Ms. Stewart told The Epoch Times in a statement. “The First and Fourth Amendments have not been wiped out of the U.S. Constitution yet.”
Computer monitoring could only be relevant if Mr. Goodwyn’s single misdemeanor trespassing crime on Jan. 6 had anything to do with computer use, but since it didn’t, the measure cannot apply to him, she said.
“The application of computer monitoring conditions to conduct invasive searches is covered extensively by case law, where the computer had to be used for the crime,” Ms. Stewart said. “And use could not have just been incidental or casual. The computer had to be integral to the crime.”
There is no speech aspect of 18 U.S. Code 1752(a)(1), the statute that covers the plea deal Mr. Goodwyn agreed to in the case, she said.
‘Minister of Disinformation’
“I am unclear and curious who the judge thinks besides himself will be the Minister of Disinformation for the court if Mr. Goodwyn expresses any views that differ from what the judge believes,” she said. “And how will the judge prevent spying on Mr. Goodwyn’s journalism, support for, and access to, Stophate.com?”
Mr. Goodwyn said he went to Jan. 6 events as a citizen journalist for the website Stophate.com. He pleaded guilty to one count of entering and remaining in a restricted building or grounds on Jan. 6.
He entered the building through the Senate wing door at 3:32 p.m. and spent 36 seconds inside the Capitol, security video shows.
Mr. Goodwyn was arrested on Jan. 29, 2021, in Sherman, Texas. He was charged in a superseding indictment on Nov. 10, 2021, with obstruction of an official proceeding, entering and remaining in a restricted building or grounds, disorderly and disruptive conduct in a restricted building or grounds, disorderly conduct in a Capitol building, and parading, demonstrating, or picketing in a Capitol building.
Mr. Goodwyn’s post-Jan. 6 speech caught the attention of Judge Walton when Mr. Goodwyn appeared on “Tucker Carlson Tonight” on Fox News Channel.
Judge Walton, when imposing a 60-day prison sentence in June 2023, said Mr. Goodwyn spread “disinformation” during Mr. Carlson’s program on March 14, 2023.
Judge Walton ordered that Mr. Goodwyn’s computer be subject to “monitoring and inspection” by a probation agent to check if he spread Jan. 6 disinformation during the term of his supervised release.
The U.S. Court of Appeals for the District of Columbia Circuit issued a per curiam order vacating the monitoring provision.
The appeals judges wrote that Judge Walton “plainly erred in imposing the computer-monitoring condition without considering whether it was ‘reasonably related’ to the relevant sentencing factors and involved ‘no greater deprivation of liberty than is reasonably necessary’ to achieve the purposes behind sentencing.”
A March 26 mandate that sent the issue back to Judge Walton said if he still wanted to impose computer monitoring, he must explain his legal reasoning, develop a record to support the provision, and ensure that what he orders follows federal supervised-release law and accords with constitutional protections.
Ms. Stewart said the logical course of action seemed clear after the Court of Appeals ruling.
“The judge had the option to simply change his sentencing judgement order to remove the computer monitoring special condition,” she said.
